TapImmune Inc. Stock Other OTC
Equities
US8760333091
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
04-30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 37.17M 50.66M |
---|---|---|---|---|---|
Net income 2024 * | -17M -23.17M | Net income 2025 * | -31M -42.25M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.26
x | P/E ratio 2025 * |
-3.26
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.79% |
Latest transcript on TapImmune Inc.
Managers | Title | Age | Since |
---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 44 | 18-10-16 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Norman Eansor
CHM | Chairman | 63 | 18-10-16 |
Steven Elms
BRD | Director/Board Member | 60 | 19-08-05 |
Katharine Knobil
BRD | Director/Board Member | 60 | 21-12-07 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.56% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |